SeaStar Medical's QUELIMMUNE Gains Traction in Pediatric Care

Introduction

SeaStar Medical Holding Corp (NASDAQ: ICU) is a commercial-stage healthcare company headquartered in Denver, Colorado. Established in 2018, the company develops cell-directed extracorporeal therapies aimed at modulating hyperinflammatory responses in critically ill patients. Its flagship technology, the Selective Cytopheretic Device (SCD), has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for six therapeutic indications. On July 8, 2025, ICU closed at $0.7447, reflecting a percentage increase of 35.72% on a volume of 3,993,187 shares.

Corporate Structure

SeaStar Medical is privately held and, according to its LinkedIn profile, employs between 2 and 10 staff. The company’s management team includes personnel with expertise in executive, clinical, regulatory, and commercial functions to support both pediatric and adult product development. Its first commercial offering, QUELIMMUNE (SCD-PED), received FDA approval in 2024 for the treatment of life-threatening acute kidney injury due to sepsis in critically ill pediatric patients.

Medical technology by National Cancer Institute

Developments and News

On June 27, 2025, a Schedule 13G filing revealed that certain investors—including Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher—collectively own 1,803,026 shares, representing 9.99% of the outstanding common stock. Two 8-K filings dated July 2 and July 8, 2025, were submitted under Items 5.07, 7.01, 8.01, and 9.01; however, detailed financial or strategic disclosures were not included in the publicly available summaries.

In June 2025, Texas Children’s Hospital, ranked No. 1 in Pediatric Nephrology by U.S. News & World Report, began offering QUELIMMUNE in its pediatric critical care unit. The Geneva Foundation was awarded a three-year grant by the U.S. Department of Defense’s Military Burn Research Program to study SCD therapy in severe burns and sepsis. Additionally, in June 2025, the U.S. Centers for Medicare & Medicaid Services agreed to cover certain expenses for Medicare and Medicaid patients enrolled in the NEUTRALIZE-CRS investigational trial of SCD therapy.

Financial and Strategic Analysis

SeaStar Medical’s market capitalization was approximately $11.6 million as of early July 2025, based on 16.14 million shares outstanding. Key trading data over the past 52 weeks shows a low of $0.31 (on June 20, 2025) and a high of $13.85 (on July 9, 2024). The company’s trailing twelve-month revenue was reported at $428,000, with a gross margin of 100%. The net margin was –3,716.12%, and EBITDA was recorded at $17.7 million.

Strategically, the FDA’s Breakthrough Device Designation may facilitate faster approvals and favorable reimbursement terms at commercial launch. A pivotal trial for the SCD therapy in adult patients requiring continuous renal replacement therapy is currently underway, addressing over 200,000 patients in the U.S. annually with no approved therapies. The CMS coverage for the NEUTRALIZE-CRS trial adds a potential benefit to the commercial outlook for later-stage studies.

Market Position and Industry Context

SeaStar Medical operates within the medical equipment manufacturing sector, focusing on extracorporeal blood purification for hyperinflammation. Currently, there are no FDA-approved treatments that directly address cytokine storms in critically ill patients, placing the SCD platform in a distinct niche for both pediatric and adult markets. Adoption by leading pediatric centers and support through federal grants indicate acknowledgment of the technology’s potential.

tl;dr

On July 8, 2025, ICU shares increased by 35.72% to $0.7447 with nearly 4 million shares traded. A June 27, 2025 Schedule 13G indicated 9.99% ownership by major investors. SeaStar Medical’s QUELIMMUNE is now utilized at Texas Children’s Hospital, and the company secured Department of Defense funding and CMS coverage for its SCD trials. Enrollment is ongoing in the pivotal adult AKI study, setting the stage for potential expanded approvals and reimbursement in future quarters.